Trichosporonosis in a tertiary care cancer center: Risk factors, changing spectrum and determinants of outcome

References

• Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989; 3: 43–52.
   PubMedGoogle Scholar
• Erer B, Galimberti M, Lucarelli G, Giardini C, Polchi P, Baronciani D, et al. Trichosporon beigelii: a life-threatening pathogen in immunocompromized hosts. Bone Marrow Transplant 2000; 25: 745–9.
   PubMed Web of Science ®Google Scholar
• Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8: 959–67.
   PubMedGoogle Scholar
• Krcmery V Jr, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, Trupl J. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole. Support Care Cancer 1999; 7: 39–43.
   Google Scholar
• Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986; 65: 268–79.
   PubMed Web of Science ®Google Scholar
• Yoss BS, Sautter RL, Brenker HJ. Trichosporon beigelii, a new neonatal pathogen. Am J Perinatol 1997; 14: 113–7.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA, 1997.
   Google Scholar
• Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromized patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
   Google Scholar
• O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR-10): 1–29.
   PubMed Web of Science ®Google Scholar
• Nasu K, Akizuki S, Yoshiyama K, Kikuchi H, Higuchi Y, Yamamoto S. Disseminated Trichosporon infection. A case report and immunohistochemical study. Arch Pathol Lab Med 1994; 118: 191–4.
   PubMedGoogle Scholar
• Haupt HM, Merz WG, Beschorner WE, Vaughan WP, Saral R. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis 1983; 147: 199–203.
   PubMed Web of Science ®Google Scholar
• Goodman D, Pamer E, Jakubowski A, Morris C, Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35–6.
   Google Scholar
• Kobayashi M, Matsuoka T, Taguchi H, Moriki T, Enzan H, Hara H, Miyoshi I. Trichosporon beigelii pneumonia in a patient with malignant histiocytosis. Jpn J Clin Oncol 1986; 16: 167–74.
   Google Scholar
• Hung CC, Chang SC, Chen YC, Tien HF, Hsieh WC. Trichosporon beigelii fungemia in patients with acute leukemia: report of 3 cases. J Formos Med Assoc 1995; 94: 127–31.
   PubMedGoogle Scholar
• Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, et al. Azole therapy for trichosporonosis: clinical evaluation of 8 patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992; 15: 781–7.
   PubMed Web of Science ®Google Scholar
• Peláez T, García-Arias V, Alcalá L, Fernandez-Chico A, Blázquez A, Guinea JV, et al. Epidemiology and in vitro antifungal susceptibilities of Trichosporon spp.: an overview of a 15-y period. Abstracts of the 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (ICAAC). Abstract M-1222, 2003.
   Google Scholar
• Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatos-plenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14: 721–39.
   PubMed Web of Science ®Google Scholar
• Surmont I, Vergauwen B, Marcelis L, Verbist L, Verhoef G, Boogaerts M. First report of chronic meningitis caused by Trichosporon beigelii. Eur J Clin Microbiol Infect Dis 1990; 9: 226–9.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616–22.
   PubMed Web of Science ®Google Scholar
• Rex JH. Editorial response: catheters and candidemia. Clin Infect Dis 1996; 22: 467–70.
   PubMed Web of Science ®Google Scholar
• Guého E, Improvisi L, de Hoog GS, Dupont B. Trichosporon in humans: a practical account. Mycoses 1994; 37: 3–10.
   PubMed Web of Science ®Google Scholar
• Perparim K, Nagai H, Hashimoto A, Goto Y, Tashiro T, Nasu M. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother 1996; 8: 445–8.
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Hachem R, Karyotakis NC, Gokaslan A, Dignani MC, Stephens LC, Tin-U CK. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob Agents Chemother 1994; 38: 2541–4.
   Google Scholar
• Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46: 1144–6.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, et al. Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis 1992; 166: 121–33.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359: 1135–44.
   PubMed Web of Science ®Google Scholar
• Karyotakis NC, Dignani MC, Hachem R, Anaissie EJ. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Anti-microb Agents Chemother 1995; 39: 571–3.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–6.
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Caspofungin Invasive Candidiasis Study Group comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–9.
   PubMed Web of Science ®Google Scholar
• Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromized patients: classification, diagnosis, and management. Clin Infect Dis 1993; 17(Suppl 2): S487–91.
   Google Scholar
• Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002; 21: 892–6.
   PubMed Web of Science ®Google Scholar